August 6, 2024Open Access

Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity—IVY Network, 26 Hospitals, October 18, 2023–March 9, 2024

Key Points

Key points are not available for this paper at this time.

Abstract

Assessing variant-specific COVID-19 vaccine effectiveness (VE) and severity can inform public health risk assessments and decisions about vaccine composition. BA.2.86 and its descendants, including JN.1 (referred to collectively as "JN lineages"), emerged in late 2023 and exhibited substantial divergence from co-circulating XBB lineages.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

C. Kevin

Centers for Disease Control and Prevention

Diya Surie

Centers for Disease Control and Prevention

Adam S. Lauring

University of Michigan

Journals

Clinical Infectious Diseases

Actions

Institutions

Stanford University

University of Washington

University of Michigan

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity—IVY Network, 26 Hospitals, October 18, 2023–March 9, 2024

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study